Bionano Genomics receives Investment Bank Analyst Rating Update
Investing.com - Bionano Genomics (NASDAQ: BNGO) reported first quarter EPS of $-0.109, worse than the analyst estimate of $-0.100. Revenue for the quarter came in at $7.4M versus...
Bionano Genomics, Inc. (BNGO), today announced the publication of three studies which collectively illustrate the continued development of data supporting optical genome mapping...
EF Hutton has initiated coverage of Bionano Genomics Inc (NASDAQ: BNGO) with a Buy rating and a price target of $1.75. The analyst says Bionano Genomics's optical genome mapping...
Bionano Genomics, Inc. is a genomics company, which provides optical genome mapping (OGM) for genome analysis. The Company offers diagnostic services to physicians specializing in medical management for individuals with genetic conditions, such as pediatric neurodevelopmental disorders, including autism spectrum disorders. It markets and sells the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation. Its Lineagen business provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, it offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.
|Average||3.675 (+476.923% Upside)|
|No. of Analysts||6|
|Moving Averages||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
|Technical Indicators||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
|Summary||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|